Skip to content
The Policy VaultThe Policy Vault

Balversa (erdafitinib) — Medica

Non-small cell lung cancer

Initial criteria

  • age ≥ 18 years
  • has metastatic disease
  • has fibroblast growth factor receptor (FGFR) alterations

Approval duration

1 year